Cisplatin

"Cisplatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.

Descriptor ID	D002945
MeSH Number(s)	D01.210.375 D01.625.125 D01.710.100
Concept/Terms	Cisplatin Cisplatin cis-Diamminedichloroplatinum(II) Platinum Diamminodichloride Diamminodichloride, Platinum cis-Platinum cis Platinum Dichlorodiammineplatinum cis-Diamminedichloroplatinum cis Diamminedichloroplatinum cis-Dichlorodiammineplatinum(II) NSC-119875 NSC-119875 Platino Platino Platinol Platinol Biocisplatinum Biocisplatinum Platidiam Platidiam

Below are MeSH descriptors whose meaning is more general than "Cisplatin".

Chemicals and Drugs [D]
Inorganic Chemicals [D01]
Chlorine Compounds [D01.210]
Cisplatin [D01.210.375]
Nitrogen Compounds [D01.625]
Cisplatin [D01.625.125]
Platinum Compounds [D01.710]
Cisplatin [D01.710.100]

Below are MeSH descriptors whose meaning is related to "Cisplatin".

Below are MeSH descriptors whose meaning is more specific than "Cisplatin".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Cisplatin" by people in this website by year, and whether "Cisplatin" was a major or minor topic of these publications.

Bar chart showing 55 publications over 24 distinct years, with a maximum of 5 publications in 2005

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1994	1	0	1
1996	1	0	1
2000	1	0	1
2001	0	1	1
2002	1	0	1
2003	0	3	3
2004	2	1	3
2005	2	3	5
2006	0	2	2
2007	0	4	4
2008	0	3	3
2009	0	3	3
2010	1	2	3
2011	1	2	3
2012	0	1	1
2013	0	1	1
2014	0	2	2
2015	1	2	3
2016	0	3	3
2017	0	2	2
2018	0	1	1
2019	1	1	2
2020	1	2	3
2021	0	3	3

Below are the most recent publications written about "Cisplatin" by people in Profiles.

Cong K, Peng M, Kousholt AN, Lee WTC, Lee S, Nayak S, Krais J, VanderVere-Carozza PS, Pawelczak KS, Calvo J, Panzarino NJ, Turchi JJ, Johnson N, Jonkers J, Rothenberg E, Cantor SB. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency. Mol Cell. 2021 08 05; 81(15):3128-3144.e7.

View in: PubMed
Rosiñol L, Beksac M, Zamagni E, Van de Donk NWCJ, Anderson KC, Badros A, Caers J, Cavo M, Dimopoulos MA, Dispenzieri A, Einsele H, Engelhardt M, Fernández de Larrea C, Gahrton G, Gay F, Hájek R, Hungria V, Jurczyszyn A, Kröger N, Kyle RA, Leal da Costa F, Leleu X, Lentzsch S, Mateos MV, Merlini G, Mohty M, Moreau P, Rasche L, Reece D, Sezer O, Sonneveld P, Usmani SZ, Vanderkerken K, Vesole DH, Waage A, Zweegman S, Richardson PG, Bladé J. Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. Br J Haematol. 2021 08; 194(3):496-507.

View in: PubMed
Calvo JA, Fritchman B, Hernandez D, Persky NS, Johannessen CM, Piccioni F, Kelch BA, Cantor SB. Comprehensive Mutational Analysis of the BRCA1-Associated DNA Helicase and Tumor-Suppressor FANCJ/BACH1/BRIP1. Mol Cancer Res. 2021 06; 19(6):1015-1025.

View in: PubMed
Nieskens TTG, Persson M, Kelly EJ, Sjögren AK. A Multicompartment Human Kidney Proximal Tubule-on-a-Chip Replicates Cell Polarization-Dependent Cisplatin Toxicity. Drug Metab Dispos. 2020 12; 48(12):1303-1311.

View in: PubMed
Miller DS, Filiaci VL, Mannel RS, Cohn DE, Matsumoto T, Tewari KS, DiSilvestro P, Pearl ML, Argenta PA, Powell MA, Zweizig SL, Warshal DP, Hanjani P, Carney ME, Huang H, Cella D, Zaino R, Fleming GF. Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209). J Clin Oncol. 2020 11 20; 38(33):3841-3850.

View in: PubMed
Regnier P, DE Luca V, Brunelle S, Sfumato P, Walz J, Rybikowski S, Maubon T, Branger N, Fakhfakh S, Durand M, Gravis G, Pignot G. Impact of sarcopenia status of muscle-invasive bladder cancer patients on kidney function after neoadjuvant chemotherapy. Minerva Urol Nephrol. 2021 04; 73(2):215-224.

View in: PubMed
Freyer DR, Brock PR, Chang KW, Dupuis LL, Epelman S, Knight K, Mills D, Phillips R, Potter E, Risby D, Simpkin P, Sullivan M, Cabral S, Robinson PD, Sung L. Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline. Lancet Child Adolesc Health. 2020 02; 4(2):141-150.

View in: PubMed
Heijink AM, Everts M, Honeywell ME, Richards R, Kok YP, de Vries EGE, Lee MJ, van Vugt MATM. Modeling of Cisplatin-Induced Signaling Dynamics in Triple-Negative Breast Cancer Cells Reveals Mediators of Sensitivity. Cell Rep. 2019 08 27; 28(9):2345-2357.e5.

View in: PubMed
Lynch MR, Tran MT, Ralto KM, Zsengeller ZK, Raman V, Bhasin SS, Sun N, Chen X, Brown D, Rovira II, Taguchi K, Brooks CR, Stillman IE, Bhasin MK, Finkel T, Parikh SM. TFEB-driven lysosomal biogenesis is pivotal for PGC1?-dependent renal stress resistance. JCI Insight. 2019 03 14; 5.

View in: PubMed
Parzuchowski A, Bush R, Pei Q, Friedman DL, FitzGerald TJ, Wolden SL, Dharmarajan KV, Constine LS, Laurie F, Kessel SK, Appel B, Fernandez K, Punnett A, Schwartz CL, Cox J, Terezakis SA. Patterns of Involved-Field Radiation Therapy Protocol Deviations in Pediatric Versus Adolescent and Young Adults With Hodgkin Lymphoma: A Report From the Children's Oncology Group AHOD0031. Int J Radiat Oncol Biol Phys. 2018 04 01; 100(5):1119-1125.

View in: PubMed

People

Explore

Similar Concepts

Top Journals